<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3911">
  <stage>Registered</stage>
  <submitdate>21/03/2013</submitdate>
  <approvaldate>21/03/2013</approvaldate>
  <nctid>NCT01845311</nctid>
  <trial_identification>
    <studytitle>ReZolve2 Clinical Investigation</studytitle>
    <scientifictitle>RESTORE II Trial: Safety &amp; Performance Study of the ReZolve2 Sirolimus-Eluting Bioresorbable Coronary Scaffold</scientifictitle>
    <utrn />
    <trialacronym>RESTORE II</trialacronym>
    <secondaryid>HCT4000</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Coronary Artery Disease</healthcondition>
    <healthcondition>Coronary Artery Stenosis</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - ReZolve2 Scaffold

Experimental: ReZolve2 Treatment Group - 


Treatment: devices: ReZolve2 Scaffold


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Major Adverse Cardiac Events (MACE)</outcome>
      <timepoint>6 Months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Major Adverse Cardiac Events</outcome>
      <timepoint>12 Months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Late Lumen Loss</outcome>
      <timepoint>9 Months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>QCA derived parameters - Late Loss, Restenosis Rate, % Diameter Stenosis &amp; Minimum Lumen Diameter</outcome>
      <timepoint>9 Months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Major Adverse Coronary Events - Major Adverse Coronary Events - Combined events consisting of death, myocardial infarction and Target Lesion Revascularization</outcome>
      <timepoint>24, 36, 48 &amp; 60 Months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>TLR - Target Lesion Revascularization</outcome>
      <timepoint>12,24,36,48 &amp; 60 Months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>TVR - Target Vessel Revascularization</outcome>
      <timepoint>12,24,36,48 &amp; 60 Months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>TVF - Target Vessel Failure</outcome>
      <timepoint>12, 24, 36, 48 &amp; 60 Month</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Acute Procedural Success - The percentage of patients meeting the Acute Technical Success criteria and the procedure results in a residual stenosis of &lt;50 percent with no immediate (in-hospital) MACE.</outcome>
      <timepoint>Day 0</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Acute Technical Success - The percentage of patients with successful delivery and deployment of the scaffold in the intended lesion without device related complications.</outcome>
      <timepoint>Day 0</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical Procedural Success - The percentage of patients meeting the Acute Procedural Success criteria with no occurrence of a MACE event through 30 days.</outcome>
      <timepoint>30 Days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Primary 

          -  Patient has evidence of myocardial ischemia or a positive functional study

          -  Patient has a normal CK-MB

          -  Target lesion has a visually estimated stenosis of =50% and &lt;100%

          -  Target lesion is located in a native coronary artery with average reference vessel
             diameter = 2.75mm and = 3.3mm

          -  Target lesion length must be = 14mm

        Primary</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patient has experienced a myocardial infarction (CK-MB or Troponin &gt; 5 X ULN) within
             72 hours of the procedure

          -  Patient has a left ventricular ejection fraction &lt; 30%

          -  Patient has unprotected lest main coronary disease with =50% stenosis

          -  The target vessel is totally occluded (TIMI Flow 0 or 1)

          -  Target lesion involves a bifurcation (a lesion with a side branch = 2.0 mm in diameter
             containing a = 50% stenosis).

          -  Target lesion is located within a bypass graft

          -  Target lesion has possible or definite thrombus</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>89</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/01/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>St Vincent's Hospital - Sydney</hospital>
    <postcode> - Sydney</postcode>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>REVA Medical, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The RESTORE II clinical trial is intended to assess safety and performance of the ReZolve2
      Bioresorbable Coronary Scaffold in native coronary arteries.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01845311</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Alexandre Abizaid, MD</name>
      <address>Instituto Dante Pazzanese de Cardiologia</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>